ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / APVO / dividends
MDCX (34) CVKD (34) DRMA (34) RDHL (52) ⌘ Pro Terminal β†’

Aptevo Therapeutics Inc. (APVO) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.35 +0.75% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.35

Aptevo Therapeutics Inc. (APVO) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $3.6M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on APVO Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is APVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Aptevo Therapeutics Inc. (NASDAQ: APVO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.35 (+0.75% 1D, market cap $3.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, APVO ranks #612 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does APVO compare to MDCX and CVKD in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APVO carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, MDCX (Medicus Pharma Ltd.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M) and CVKD (Cadrenal Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M). Among the 5-stock peer group, APVO leads on earnings multiple (N/A) while APVO leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for APVO?
β–Ό

Per APVO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671584), Aptevo Therapeutics Inc. generated $73.7M in revenue (+7.0% YoY), -$26.0M in net income, and -$25.6M in free cash flow against $27.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.35 (-0.05%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (35/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510035
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (7)Whales (3)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.4% Base Target
$29 Bull$1 Base$1 Bear
πŸ“¬ FREE APVO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for APVO)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
πŸ” WHY APVO SCORES 35/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–² #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 29.1 (OVERSOLD (<32))

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
43
Grade D$1.73-7.5% Next Q
Q2 (-2Q)
40
Grade D$1.60-18.8% Next Q
Q3 (-1Q)
38
Grade E$1.30+3.8% Next Q
Current
35
Grade D-$1.35-8.5% Hist 90D Ξ±
Trajectory: D (43) β†’ D- (35)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a APVO Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While APVO currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.78) and Max Pain ($1.42) forces dealer call-delta covering toward $29.48.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APVOβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œAPVO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APVO)

  • βœ“Walkthrough of APVO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
APVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -74.77%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-04O $1.34H $1.35L $1.34C $1.35VOL 23.1K
RES: $3.44SUP: $1.23SMA50: $1.78SMA200: $4.25
$20.91$15.58$10.25$4.92$-0.40RES $3.44SUP $1.23$1.352026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ APVO Butterfly Map β†’ + Track APVO β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +7.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on APVO today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for APVO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for APVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APVO)

Health Care Rank #612 of 1015 βš”οΈ MDCX vs APVO Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (APVO vs. MDCX, CVKD, DRMA, RDHL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Aptevo Therapeutics Inc. (APVO) ranks #612 by composite RQD confidence (35/100, grade D-) and #962 by equity capitalization ($3.6M). Within this direct 5-issuer industry benchmark cohort, APVO leads on earnings valuation at N/A trailing P/E, while APVO leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. RDHL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with APVO at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
APVO ACTIVE
Aptevo Therapeutics Inc.
D- 35/100 β€” β€” -35.0% +0.75% $3.6M Benchmark Subject
MDCX
Medicus Pharma Ltd.
E 34/100 β€” β€” -35.0% +2.66% $3.7M /mdcx-vs-apvo β†’
CVKD
Cadrenal Therapeutics Inc.
E 34/100 β€” β€” -35.0% +5.58% $3.7M /cvkd-vs-apvo β†’
DRMA
Dermata Therapeutics Inc.
E 34/100 β€” β€” -35.0% -2.73% $3.7M /drma-vs-apvo β†’
RDHL
Redhill Biopharma Ltd.
D+ 52/100 β€” β€” β€” +13.87% $3.9M /rdhl-vs-apvo β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001671584 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aptevo Therapeutics Inc. (APVO) reported GAAP revenue of $73.7M (+7.0% vs. FY2024 revenue of $68.9M , and -8.9% cumulative change since FY2023) , GAAP net income of -$26.0M, operating cash flow of -$25.6M, and free cash flow of -$25.6M (-7.6% YoY). On the balance sheet, APVO closed FY2025 with $27.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $73.7M -$26.0M -$25.6M -$25.6M $27.2M β€”
FY2024 (FY) 2024-12-31 $68.9M -$24.1M -$23.8M -$23.8M $15.6M β€”
FY2023 (FY) 2023-12-31 $80.9M -$17.4M -$11.7M -$11.7M β€” β€”

3. APVO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Aptevo Therapeutics Inc. (NASDAQ: APVO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.35 (+0.75% 1D, market cap $3.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, APVO ranks #612 in composite RQD confidence.

How does APVO compare to MDCX and CVKD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APVO carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, MDCX (Medicus Pharma Ltd.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M) and CVKD (Cadrenal Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M). Among the 5-stock peer group, APVO leads on earnings multiple (N/A) while APVO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for APVO?

Per APVO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671584), Aptevo Therapeutics Inc. generated $73.7M in revenue (+7.0% YoY), -$26.0M in net income, and -$25.6M in free cash flow against $27.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is APVO trading relative to its 50-day, 200-day, and 52-week technical levels?

APVO last traded at $1.35 (+0.75% on volume of 23,050 shares), positioning the stock -24.16% below its 50-day simple moving average ($1.78) and -68.24% below its 200-day simple moving average ($4.25). Across its 52-week range of $1.25 to $28.08, APVO sits at the 0.4% percentile with a 14-day RSI of 29.1 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.18 to $1.52).

Direct Sub-Reports: APVO RQD Cockpit APVO 12M Forecast APVO Earnings & Move APVO Dividends & DRIP APVO Insiders & 13F APVO Whale Options APVO Profit Sankey APVO News & Why
ROARABLE RATING BRIEF β€’ RQD 35/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

APVO β€” Aptevo Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Aptevo Therapeutics Inc. (APVO) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.35 (+0.75% 1D, market capitalization $3.6M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Aptevo Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry,. Reported revenue for FY 2025, FY 2024, and FY 2023 is β€” in each period, indicating no reported revenue in the supplied periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Aptevo Therapeutics Inc. (APVO) reported $73.7M in annual revenue (up from $68.9M in FY2024, +7.0% YoY) and -$26.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($80.9M revenue, -$17.4M net income) through FY2025, APVO scaled operating cash flow to -$25.6M and free cash flow to -$25.6M, backed by $27.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.25 – $28.08 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), APVO carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can APVO sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $73.7M and free cash flow of -$25.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is APVO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

APVO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aptevo Therapeutics Inc. (APVO) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to APVO Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

APVO Bull vs. Bear Conversation Board β€” What's Your Call at $1.35?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON APVO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on APVO:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $1.66 (+23.9%)
πŸ“Œ Pinned Debate

Reported cash rose from $8.7M in FY 2024 to $21.6M in FY 2025, per the SEC financials.

Here is why I am bullish on APVO here at $1.34: Reported cash rose from $8.7M in FY 2024 to $21.6M in FY 2025, per the SEC financials.. Compare APVO's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $1.27 are getting bought.

RetailWhale_TX πŸ‚ BULL

@ShortSeller_Dan Shorting a 3/20 institutional whale-flow stock at $1.34 is dangerous when funds are rotating into Health Care.

SH ShortSeller_Dan RQD DEBATE OPENER β€’ Forensic Short Bias 🐻 BEARISH 🎯 Target: $1.13 (-15.7%)
Spot @ $1.34

The RQD rating shows ROIC of -35% and FCF yield of 0%, alongside a Piotroski F-Score of 2/9.

I respect the product at Aptevo Therapeutics Inc., but the stock at $1.34 is a different story. The RQD rating shows ROIC of -35% and FCF yield of 0%, alongside a Piotroski F-Score of 2/9.. FCF yield is 0.0% and RQD sits at 35/100 (D-) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE